Krystal Biotech, Inc..
biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 40
What's happening
Earlier this month
One to three months ago
-
Krystal Biotech, Inc. and Palvella Therapeutics, Inc. were compared based on investment metrics.Some support1 report
-
Krystal Biotech stock is seeing increased institutional investment activity, with related filings made on the SEC regarding its trading on the Nasdaq exchange.Some support1 report
-
Insider sales of Krystal Biotech stock were disclosed to the SEC by executives.Some support2 reports
-
Krystal Biotech, Inc. focuses on genetic medicines in the US.Well supported5 reports1 development inside
Gone quiet
No new reports in 90+ days-
Krystal Biotech stock trades on Nasdaq, and Citigroup provides analyst ratings and price targets for the company.Some support2 reports
-
Trump pledged to unleash American oil and gas, involving Krystal Biotech, Inc.Speculative1 report
-
Krystal Biotech maintained nationwide access in the US and received VYJUVEK approval in Japan for DEB treatment.Some support4 reports
-
Krystal Biotech, Inc. and Coherus Oncology are two companies that operate within the same industry, as of June 25, 2025.Speculative1 report
-
Krystal Biotech focuses on US genetic medicines, while IREN's growth surpasses the US market average and Anthony Lewis was appointed CCO.Speculative2 reports
-
Krystal Biotech focuses on genetic medicines for high unmet needs, while Atlassian designs and develops software.Speculative1 report
-
Suma Krishnan was appointed President of Research & Development at Krystal Biotech, Inc.Speculative1 report
-
AI is changing healthcare and impacting drug discovery, involving Plus Therapeutics and Animation International.Some support2 reports
-
Krystal Biotech underperformed the market so far this year as of August 4, 2025.Some support1 report
-
BofA lowered its price target for Krystal Biotech, citing growth concerns in August 2025.Some support1 report
-
Krystal Biotech, Inc. reached out to the FDA following promising early evidence.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Krystal Biotech, Inc. this week
News at the entities that move Krystal Biotech, Inc. most-
FDA StructuralFDA conducted inspections in Patiala, leading to allegations of harassment by state authorities against a local chemists association.Moves Krystal Biotech, Inc.
-
Royal Bank of Canada TransactionalRoyal Bank of Canada and First Premier Bank increased their positions in the Invesco RAFI Strategic US ETF on October 24, 2026.Moves Krystal Biotech, Inc.
-
TD Cowen TransactionalGoldman Sachs, TD Cowen, and Barclays cited valuation and growth concerns, leading to downgrades on July 25, 2026.Moves Krystal Biotech, Inc.
-
MarketBeat Mentioned togetherMarketBeat was used to provide rating data for Cresco Labs on August 5, 2026.Moves Krystal Biotech, Inc.
-
Citigroup Mentioned togetherCitigroup restated a buy rating on shares of Intensity Therapeutics.Moves Krystal Biotech, Inc.
-
Jefferies Financial Group TransactionalAclara Resources Inc. has a module project in Goiás, and Jefferies Financial Group began coverage on the company.Moves Krystal Biotech, Inc.
Connections
The 15 strongest of 40, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Suma Krishnan Structural
Suma Krishnan holds the executive role of President, Research & Development at Krystal Biotech, Inc.
-
John Charles Thomas Structural
John Charles Thomas serves as the Executive Vice President of Krystal Biotech, Inc.
-
FDA Structural
The FDA formally regulates and approves Krystal Biotech's commercial products.
-
Royal Bank of Canada Transactional
Royal Bank of Canada has increased its financial stake in Krystal Biotech, Inc. stock holdings.
-
Securities and Exchange Commission Structural
Krystal Biotech is required to file mandatory disclosures regarding share holdings and institutional investment activity with the SEC.
-
TD Cowen Transactional
TD Cowen provided a buy rating and raised the price target for Krystal Biotech.
-
Jefferies Financial Group Transactional
Jefferies Financial Group issued buy ratings and price targets for Krystal Biotech.
-
MarketBeat Mentioned together
MarketBeat provides consensus ratings and analyst coverage for Krystal Biotech.
Show all 15 connections
-
Citigroup Mentioned together
Citigroup provides analyst ratings and price targets for Krystal Biotech, functioning as a key market information source.
-
Relay Therapeutics Mentioned together
Both companies are identified as mid-cap healthcare companies.
-
LinkedIn Mentioned together
Krystal Biotech uses LinkedIn as a platform to follow industry updates.
-
Europe Shared context
Krystal Biotech operates and receives regulatory approvals for its products within the European market.
-
Bank of America Mentioned together
The relationship is characterized by the influence of analyst firms on stock price targets due to market coverage.
-
Pittsburgh Shared context
Krystal Biotech is headquartered in Pittsburgh.
-
Nasdaq Shared context
Krystal Biotech, Inc. is listed and trades its stock on the Nasdaq exchange.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsShow 2 earlier months
July 2026
1 eventJune 2026
12 events- Krystal Biotech, Inc. focuses on genetic medicines in the US.
- Krystal Biotech stock trades on Nasdaq, and Citigroup provides analyst ratings and price targets for the company.
- Trump pledged to unleash American oil and gas, involving Krystal Biotech, Inc.
- Krystal Biotech maintained nationwide access in the US and received VYJUVEK approval in Japan for DEB treatment.
- Krystal Biotech, Inc. and Coherus Oncology are two companies that operate within the same industry, as of June 25, 2025.
- Krystal Biotech focuses on US genetic medicines, while IREN's growth surpasses the US market average and Anthony Lewis was appointed CCO.
- Krystal Biotech focuses on genetic medicines for high unmet needs, while Atlassian designs and develops software.
- Suma Krishnan was appointed President of Research & Development at Krystal Biotech, Inc.
- AI is changing healthcare and impacting drug discovery, involving Plus Therapeutics and Animation International.
- Krystal Biotech underperformed the market so far this year as of August 4, 2025.
- BofA lowered its price target for Krystal Biotech, citing growth concerns in August 2025.
- Krystal Biotech, Inc. reached out to the FDA following promising early evidence.